Steven Cohen Alnylam Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 201,396 shares of ALNY stock, worth $91.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

201,396

Previous 300,635 33.01%

Holding current value

$91.9 Million

Previous $81.2 Million 19.1%

% of portfolio

0.15%

Previous 0.2%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$224.32 - $326.09 $22.3 Million - $32.4 Million	-99,239 Reduced 33.01%	201,396 $65.7 Million
Q1 2025 May 15, 2025	BUY	$233.07 - $290.7 $70.1 Million - $87.4 Million	300,635 New	300,635 $81.2 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $17.6 Million - $23.8 Million	120,265 Added 139.86%	206,255 $30.8 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $13 Million - $16.9 Million	85,990 New	85,990 $16.5 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $44.1 Million - $73.9 Million	-318,630 Reduced 95.63%	14,570 $2.92 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $40.1 Million - $56.4 Million	333,200 New	333,200 $48.6 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $15.9 Million - $20.8 Million	-99,512 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $3.43 Million - $4.19 Million	-20,177 Reduced 16.86%	99,512 $18.8 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $41.2 Million - $56.6 Million	-320,248 Reduced 72.79%	119,689 $20.3 Million
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $5.32 Million - $7.37 Million	-41,963 Reduced 8.71%	439,937 $62.1 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $59.3 Million - $70.8 Million	481,900 New	481,900 $62.6 Million
Q3 2019 Nov 15, 2019	SELL	$70.9 - $87.82 $28.3 Million - $35 Million	-398,928 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $26.3 Million - $37 Million	398,928 New	398,928 $28.9 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $55.5 Million - $78.2 Million	-885,312 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $41.2 Million - $57.8 Million	-471,096 Reduced 34.73%	885,312 $77.5 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $39.6 Million - $48.3 Million	448,362 Added 49.38%	1,356,408 $134 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $95 Million - $122 Million	819,160 Added 921.58%	908,046 $108 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $444,908 - $543,962	3,886 Added 4.57%	88,886 $11.3 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $6.17 Million - $10.1 Million	85,000	85,000 $9.99 Million

Others Institutions Holding ALNY

# of Institutions

744

Shares Held

115M

Call Options Held

584K

Put Options Held

672K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $56.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account